Individual patient data network meta-analysis of mortality effects of implantable cardiac devices

Heart

Volumn 101, Issue 22, 2015, Pages 1800-1806

  Woods, B ^a,b   Hawkins, N ^b,c   Mealing, S ^b   Sutton, A ^d   Abraham, W T ^e   Beshai, J F ^f   Klein, H ^g   Sculpher, M ^a,b   Plummer, C J ^h   Cowie, M R ⁱ  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ICON CLINICAL RESEARCH   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CARDIAC IMPLANT; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DATA SYNTHESIS; DEVICE COMPARISON; DEVICE THERAPY; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; PREDICTION; PRIORITY JOURNAL; QRS INTERVAL; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME;

EID: 84948570545     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-307634     Document Type: Article

References (39)

1. Yancy CW, Jessup M, Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-239.
2. McMurray JJ, Adamopoulos S, Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787-847.
3. National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120). NICE technology appraisal guidance 314. NICE, 2014:1-71.
4. Sipahi I, Carrigan TP, Rowland D.Y., et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011; 171:1454-62.
5. Sipahi I, Chou JC, Hyden M, et al Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163:260-7.
6. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol 2012; 23:163-8.
7. Cleland JG, Abraham WT, Linde C, et al An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34:3547-56.
8. Wells G, Parkash R, Healey J.S., et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ 2011; 183:421-9.
9. Santangeli P, Pelargonio G, Dello Russo A, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 2010; 7:876-82.
10. Bardy GH, Lee KL, Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. [Erratum appears in N Engl J Med 2005; 352:2146].
11. N Engl J Med 2005; 352:225-37.
12. Tang AS, Wells GA, Talajic M, et al Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363:2385-95.
13. Moss AJ, Hall WJ, Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med2009; 361:1329-38.
14. Caldwell DM, Ades AE, Higgins JP Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.
15. Anand IS, Carson P, Galle E., et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2009; 119:969-77.
16. Bristow MR, Saxon LA, Boehmer J, et al Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-50.
17. Bristow MR, Feldman AM, Saxon LA Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail 2000; 6:276-85.
18. Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.[Erratum appears in J Am Coll Cardiol.2008 Jun 3; 51(22): 2197 Note: Ghali, Jalil [corrected to Ghali, Jalal]].
19. J Am Coll Cardiol 2005; 46:2329-34.
20. Linde C, Abraham WT, Gold M.R., et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52:1834-43.
21. Higgins SL, Hummel JD, Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454-9.
22. Young JB, Abraham WT, Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289:2685-94.
23. Abraham WT, Young JB, Leon A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004; 110:2864-8.
24. Tudur-Smith C., Marson AG, Chadwick D.W., et al. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007; 8:34.
25. Woods BS, Hawkins N, Scott DA Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010; 10:54.
26. Cleland JG, Freemantle N, Erdmann E., et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012; 14:628-34.
27. Goldenberg I, Gillespie J, Moss A.J., et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010; 122:1265-71.
28. Tudur-Smith C., Williamson R, Marson AG Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005; 24:1307-19.
29. Collett D. Modelling survival data in medical research. 2nd edn. Florida: Chapman and Hall CRC, 2003.
30. Spertus JA, Bach R, Bethea C., et al. Improving the process of informed consent for percutaneous coronary intervention: Patient Outcomes from the Patient Risk Information Services Manager (ePRISM) study. Am Heart J 2015; 169: 234-241. e1.
31. Kramer DB, Brock DW, Tedrow UB Informed consent in cardiac resynchronization therapy what should be said? Circ Cardiovasc Qual Outcomes 2011; 4:573-7.
32. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007; 335:925.
33. Saxon LA, Bristow MR, Boehmer J, et al Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114:2766-72.
34. Abildstrom SZ, Rask-Madsen C, Ottesen M.M., et al. Impact of age and sex on sudden cardiovascular death following myocardial infarction. Heart 2002; 88:573-8.
35. Tung P, Albert CM Causes and prevention of sudden cardiac death in the elderly. Nat Rev Cardiol 2013; 10:135-42.
36. Levy WC, Mozaffarian D, Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424-33.
37. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34:2281-329.
38. Packer DL, Prutkin JM, Hellkamp A.S., et al. Impact of implantable cardioverterdefibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. [Erratum appears in Circulation. 2010 Feb 16; 121(6):e39].
39. Circulation 2009; 120:2170-6.